Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9327324 | Gynecologic Oncology | 2005 | 5 Pages |
Abstract
Currently, there are no good criteria for predicting which patients with complex atypical hyperplasia/grade 1 endometrioid adenocarcinoma will optimally respond to progestin therapy. There is some evidence that endometrial complex hyperplasia demonstrating loss of MLH1 protein by immunohistochemistry is strongly related to subsequent or concurrent endometrial cancer, especially tumors of higher grade and stage. In a woman with a biopsy diagnosis of endometrial hyperplasia, evaluation of MLH1 protein status by immunohistochemistry may provide useful information when medical management is being considered.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Jennifer M. Rubatt, Brian M. Slomovitz, Thomas W. Burke, Russell R. Broaddus,